Only Daxor’s BVA Diagnostic Was Shown to Accurately Reflect Blood Volume Compared to Inferior Surrogates

Oak Ridge, TN – March 8, 2024 — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data from Duke University Medical Center validating the benefits of blood volume analysis (BVA) in optimizing individualized therapy for heart failure patients with impaired renal function.  Data were presented on 259 patients from three centers at the Technology and Heart Failure Therapeutics Conference (THT), which brought together the world’s leading experts in heart failure innovations at the Westin Boston Seaport in Boston, Massachusetts March 4-6, 2024.

The lead investigator from Duke, Veraprapas Kittipibul M.D., commented during his award-winning presentation that surrogate markers such as “right atrial pressure and capillary wedge pressure had minimal utility to measure blood volume.”  The study definitively showed the limitations of these commonly used measures of pressure to guide volume decisions, compared with Daxor’s 98% accurate BVA system.